{
  "id": 4953139,
  "title": "Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Colombia",
  "url": "https://urgent.news/2026/09/01/knight-therapeutics-announces-regulatory-approval-of-tavalisse-in",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-01T22:04:52.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/knight-therapeutics-announces-regulatory-approval-of-tavalisse-in-colombia"
  },
  "original_language": "en",
  "account": null,
  "summary": "MONTREAL, Sept. 01, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has received regulatory approval from INVIMA, the Colombian health regulatory agency, for TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}